Stuttering Clinical Trial
Official title:
The Blank Center CARE Model™: An Anti-Ableist Approach to Treatment
The purposes of this study are to 1) investigate potential speech, language, and psychosocial contributions to the experience of stuttering in monolingual and multilingual speakers, and to 2) evaluate interdisciplinary, telehealth, and speech-language pathology treatment methods and clinical training specific to fluency disorders.
Stuttering is a neurophysiological communication disorder characterized by a disruption in the forward flow of speech. Stuttering is multifactorial in nature, meaning there are several factors that likely to contribute to the development of stuttering in children and persistence of stuttering into adulthood. About 1% of the worldwide population stutters. In the United States, over 3 million people stutter. Research suggests people who stutter present with negative cognitive and affective components of the disorder, and that the general population holds negative perceptions of stuttering. Historically, people who stutter spend thousands of dollars on treatment that is not effective in mitigating the negative impact of stuttering on their overall communication and quality of life. Speech-language pathologists evaluate and treat persons who stutter across the lifespan. Research suggests speech-language pathologists report fluency disorders (stuttering and cluttering) as the communication disorders with which they feel least competent and comfortable. Thus, the purposes of this study are to 1) investigate potential speech, language, psychosocial, and motor contributions to stuttered speech production in monolingual and multilingual speakers and to 2) evaluate interdisciplinary, telehealth, and speech-language pathology treatment methods and clinical training tools specific to fluency disorders. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Suspended |
NCT01684657 -
A Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Tolerability of Asenapine With Flexible Dosing From 5mg to 20mg in Adults With Developmental Stuttering
|
Phase 3 | |
| Not yet recruiting |
NCT05437627 -
Computerized Based Analysis for Detection and Severity Assessment of Stuttering
|
||
| Completed |
NCT02288598 -
Enhancing Speech Fluency With Non-invasive Brain Stimulation in Developmental Stuttering
|
N/A | |
| Completed |
NCT00001602 -
Genetic Factors Related to Stuttering
|
N/A | |
| Active, not recruiting |
NCT04082104 -
Assessment of Stuttering Severity in Adults and Adolescences in Conversational and Narrative Contexts
|
||
| Completed |
NCT04580966 -
IBSR Intervention for Adults Who Stutter
|
N/A | |
| Recruiting |
NCT00148161 -
Activity of the Auditory Cortex During Speech Perception and Speech Production in Stuttering
|
N/A | |
| Completed |
NCT00001551 -
Characteristics of Idiopathic Familial Speech Disorders
|
N/A | |
| Withdrawn |
NCT01315730 -
The Effects of Tactile Speech Feedback on Stuttering Frequency
|
Phase 1 | |
| Completed |
NCT00004991 -
Study of Brain Activity During Speech Production and Speech Perception
|
N/A | |
| Recruiting |
NCT05286151 -
Network Connectivity and Temporal Processing in Adolescents Who Stutter
|
N/A | |
| Completed |
NCT00001604 -
Genetic Linkage Studies of Stuttering
|
||
| Recruiting |
NCT00680303 -
Spacing Lidcombe Program Clinic Visits
|
Phase 2 | |
| Recruiting |
NCT00709072 -
Follow-up of Children After Stuttering Treatment
|
Phase 2 | |
| Completed |
NCT00830154 -
A Study to Assess the Efficacy and Safety of Pagoclone for Adults With Stuttering
|
Phase 2/Phase 3 | |
| Completed |
NCT03698539 -
How Stuttering and Gestures Influence the Intelligibility of Individuals With Down Syndrome
|
||
| Completed |
NCT04505696 -
Providing Speech Therapy Awareness in Private Schools
|
N/A | |
| Recruiting |
NCT04929184 -
Speech Processing in Stuttering
|
N/A | |
| Terminated |
NCT00001308 -
Central Mechanisms in Speech Motor Control Studied With H215O PET
|
||
| Completed |
NCT01097161 -
Stuttering and Apraxia of Speech: the Efficacy of an Intervention Program
|
N/A |